Fusion Antibodies Plc ( (GB:FAB) ) has shared an update.
Fusion Antibodies plc announced that its issued share capital consists of 104,902,120 ordinary shares, each with one voting right. This information is crucial for shareholders to determine their interests under the FCA’s Disclosure Guidance and Transparency Rules. The company’s growth strategy focuses on leveraging technological advances to expedite the drug development process, positioning itself as a key player in the pharmaceutical and diagnostic sectors.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a wide range of services, including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a strong international client base, including eight of the top 10 global pharmaceutical companies by revenue, and aims to accelerate drug development processes through innovative platforms.
YTD Price Performance: -7.80%
Average Trading Volume: 1,283,576
Technical Sentiment Signal: Hold
Current Market Cap: £6.82M
Learn more about FAB stock on TipRanks’ Stock Analysis page.